• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Tudriqev Launch Could Matter For Replimune Stock (REPL)

    Simply Wall St·10/08/2026 11:41:58
    语音播报
    • Replimune Group has made TUDRIQEV, its HSV-1 based oncolytic viral therapy for PD-1-experienced unresectable advanced cutaneous melanoma, commercially available in the US. Treatment is given by intratumor injection alongside nivolumab under an accelerated FDA approval that is supported by ongoing confirmatory trials.
    • The launch ties a complex, procedure-based product to a dedicated support hub, ReplimuneConnect Plus, which addresses access, reimbursement, and financial assistance. Execution on distribution, specialist training, and payer pull-through now becomes a core operational test for Replimune Group.
    • We will now look at how Replimune Group's investment narrative could be influenced by TUDRIQEV's US launch and access program.
    Spot 35 healthcare AI stocks that, like Replimune Group, are trying to reshape how complex cancers are treated with targeted biology and immunotherapy.

    What Is Replimune Group's Investment Narrative?

    To own Replimune Group, you need to be comfortable backing a commercial build out rather than a mature revenue story. TUDRIQEV’s US launch finally moves the business from pre commercial into a real world test of operations, physician uptake, and payer behavior. The near term hinges on execution around a complex, procedure heavy product and on whether ReplimuneConnect Plus actually removes friction for hospitals and clinics that need support on reimbursement and handling risk.

    Everything else lines up behind that single question. The company still reports no meaningful revenue, carries ongoing losses, and is forecast to remain unprofitable over the next three years. As a result, TUDRIQEV uptake plus progress in the IGNYTE 3 confirmatory trial are the main practical catalysts. Persistent share volatility, prior dilution, and a rich P/B multiple against peers mean the story works only if you are comfortable that...

    There's only one way to know the right time to buy, sell or hold Replimune Group. Head to Simply Wall St's company report for the latest analysis of Replimune Group's Fair Value.

    NasdaqGS:REPL 1-Year Stock Price Chart
    NasdaqGS:REPL 1-Year Stock Price Chart

    Exploring Other Perspectives

    Replimune Group’s most bullish analysts lean hard into the revenue catalyst. Before this TUDRIQEV news, they were modeling revenue of about US$458.6 million and earnings of roughly US$84.4 million by 2029, based on a 40.9x P/E. You should expect those projections to be revisited as the real launch data comes through.

    Explore 2 other Replimune Group fair value estimates, including one that suggests up to 713% upside from the current price!

    Form Your Own Verdict

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Ideas Beyond Replimune Group?

    If TUDRIQEV and Replimune Group have sharpened your interest in complex therapies and earlier stage commercial stories, it can help to compare them with other businesses at very different points in their journey.

    The Simply Wall St Screener lets you quickly filter for stocks that match the risk, balance sheet strength, and upside profile you actually want, rather than what the market happens to be talking about today.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.